Skip to main content
Thomas Gajewski, MD, Oncology, Chicago, IL, University of Chicago Medical Center

ThomasFGajewskiMD

Oncology • Chicago, IL

Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Gajewski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Gajewski's full profile

Already have an account?

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 1995 - 1997
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 1991 - 1993
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1991

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 1991 - 2026

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Elected Member The American Society for Clinical Investigation, 2006

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • The Microbiome in Cancer Immunotherapy: Diagnostic Tools and Therapeutic Strategies  
    Thomas Gajewski, MD, Science Magazine

Lectures

  • Evaluation of Imaging Techniques in Immune Checkpoint Therapy 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • AACR 2022 Recap: T Cells Still on Top, but Make Room for Myeloid Cells
    AACR 2022 Recap: T Cells Still on Top, but Make Room for Myeloid CellsApril 14th, 2022
  • The AACR Annual Meeting Is Virtual for a Second Consecutive Year
    The AACR Annual Meeting Is Virtual for a Second Consecutive YearApril 26th, 2021
  • Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer Immunotherapy
    Bicara Therapeutics Launches with Deep Pipeline of First-in-Class Dual Action Biologics for Cancer ImmunotherapyMarch 15th, 2021
  • Join now to see all

Grant Support

  • Program 3 (Immunology And Cancer)National Cancer Institute2008–2012
  • Human Immunologic MonitoringNational Cancer Institute2008–2012
  • Innate Factors In Tumor Antigen Cross-PresentationNational Cancer Institute2008–2011
  • Countering Immune Resistance In The Melanoma Tumor MicroenvironmentNational Cancer Institute2007–2011
  • DGK In T Cell Regulation And ToleranceNational Institute Of Allergy And Infectious Diseases2009–2010
  • T Cell Responsiveness And Homeostasis In Anti-TumorNational Cancer Institute2006–2010
  • Deletion Of Inhibitory Genes In Post-Thymic T Cells To Study Immune ToleranceNational Institute Of Allergy And Infectious Diseases2008–2009
  • Multi-Peptide/Il 12 Melanoma VaccineNational Cancer Institute2003–2006
  • Molecular Dissection Of T Cell AnergyNational Institute Of Allergy And Infectious Diseases2004–2005
  • Biochemical/Molecular Changes Upon Naive T Cell PrimingNational Institute Of Allergy And Infectious Diseases2001–2005
  • Technologies To Block Gene Expression In Normal T CellsNational Institute Of Allergy And Infectious Diseases2002–2003
  • Core--Human Immunologic MonitoringNational Cancer Institute2002
  • MAGE-3 PLUS IL-12 Immunization In Metastatic MelanomaNational Center For Research Resources1998–2002

Hospital Affiliations

Dr. Thomas Gajewski, Dr. Thomas Gajewski, MD, Dr. T Gajewski, Dr. Thomas F Gajewski